Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05430854 · ClinicalTrials.gov registry record · Phase 2
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT05430854 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 155 participants.
The verdict
NCT05430854, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.
Interventions
- BIOLOGICAL Daxdilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05430854
The ClinicalTrials.gov registry entry for NCT05430854 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daxdilimab is the first listed.
NCT05430854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05430854 about?
NCT05430854 is a clinical study titled "Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study". A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.
What is the current status of trial NCT05430854?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2022-06-01. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT05430854?
The interventions under investigation include: Daxdilimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05430854?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.